When significant safety questions arise during a trial, the FDA has the option to place a full or partial clinical hold on treatment and new enrollment. Clinical holds are designed to protect patients from serious harm but they can also cause expensive delays for drug developers and frustrations for patients. While some problems can be resolved quickly, others can permanently derail a drug's development.
from Cancer via ola Kala on Inoreader http://ift.tt/2fg707V
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου